Small Molecules

29 Jun 2007 Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease
29 Jun 2007 Cytochroma reports positive Phase I clinical data for CTA018 injection
29 Jun 2007 Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
29 Jun 2007 4SC AG: patient recruitment successfully completed for phase IIa clinical trial
29 Jun 2007 Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
29 Jun 2007 ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
29 Jun 2007 Biotie Therapies corp. stock exchange release
29 Jun 2007 VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
29 Jun 2007 Speedel reports successful SPP635 Phase IIa trial in hypertension
29 Jun 2007 Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
29 Jun 2007 Cylene Pharmaceuticals' Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
29 Jun 2007 Shire Announces Filing of VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adults
29 Jun 2007 Cytokinetics Announces Data From Phase II Clinical Trial of Ispinesib in Breast Cancer
29 Jun 2007 Cyclacel Pharmaceuticals announces results of Phase II Seliciclib combination studies
28 Jun 2007 GlaxoSmithKline's Arixtra(R) (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes
28 Jun 2007 Preliminary results for phase III study evaluating CellCept in lupus nephritis
28 Jun 2007 SurModics and Merck Enter Ophthalmic License and Research Collaboration Agreement
28 Jun 2007 Isotechnika achieves full enrolment for ISA247 Phase 2b kidney transplant trial
28 Jun 2007 Chelsea Therapeutics Initiates CH-1504 Bioequivalence Study
28 Jun 2007 DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
28 Jun 2007 FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV
27 Jun 2007 Incitive Reports Successful Results for Lead Compound
27 Jun 2007 Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
27 Jun 2007 Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
27 Jun 2007 Koronis Pharmaceuticals Begins Phase 2a Proof of Concept Study of KP-1461, a Novel, Viral Decay Acceleration Agent for HIV Infection

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up